Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lunzer

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
ACS Pharmacology & Translational Science|January 16, 2025
Recommended Opioid Receptor Tool Compounds: Comparative <i>In Vitro</i> for Receptor Selectivity Profiles and <i>In Vivo</i> for Pharmacological Antinociceptive ProfilesLinh T Tran, Katie T Freeman, Mary M Lunzer, et al.
Hypertension (Dallas, Tex. : 1979)|August 1, 1997
Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardiumS A Katz, J A Opsahl, M M Lunzer, et al.
Arthritis Research & Therapy|July 29, 2018
A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic toleranceRaini Dutta, Mary M Lunzer, Jennifer L Auger, et al.
Neuroscience|February 22, 2023
MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated MiceGiuseppe Cataldo, Mary M Lunzer, Eyup Akgün, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociceptionEyup Akgün, Muhammad I Javed, Mary M Lunzer, et al.
ACS Chemical Neuroscience|October 3, 2017
Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into MiceDanielle N Adank, Mary M Lunzer, Cody J Lensing, et al.
Journal of Medicinal Chemistry|October 10, 2015
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)Eyup Akgün, Muhammad I Javed, Mary M Lunzer, et al.
ACS Chemical Neuroscience|September 29, 2012
Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeysAjay S Yekkirala, Matthew L Banks, Mary M Lunzer, et al.
Pain|April 30, 2020
The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioidsRebecca Speltz, Mary M Lunzer, Sarah S Shueb, et al.
Journal of Medicinal Chemistry|June 6, 2013
Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of toleranceMorgan Le Naour, Eyup Akgün, Ajay Yekkirala, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
ACS Pharmacology & Translational Science|January 16, 2025
Recommended Opioid Receptor Tool Compounds: Comparative <i>In Vitro</i> for Receptor Selectivity Profiles and <i>In Vivo</i> for Pharmacological Antinociceptive ProfilesLinh T Tran, Katie T Freeman, Mary M Lunzer, et al.
Hypertension (Dallas, Tex. : 1979)|August 1, 1997
Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardiumS A Katz, J A Opsahl, M M Lunzer, et al.
Arthritis Research & Therapy|July 29, 2018
A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic toleranceRaini Dutta, Mary M Lunzer, Jennifer L Auger, et al.
Neuroscience|February 22, 2023
MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated MiceGiuseppe Cataldo, Mary M Lunzer, Eyup Akgün, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociceptionEyup Akgün, Muhammad I Javed, Mary M Lunzer, et al.
ACS Chemical Neuroscience|October 3, 2017
Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into MiceDanielle N Adank, Mary M Lunzer, Cody J Lensing, et al.
Journal of Medicinal Chemistry|October 10, 2015
Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)Eyup Akgün, Muhammad I Javed, Mary M Lunzer, et al.
ACS Chemical Neuroscience|September 29, 2012
Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeysAjay S Yekkirala, Matthew L Banks, Mary M Lunzer, et al.
Pain|April 30, 2020
The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioidsRebecca Speltz, Mary M Lunzer, Sarah S Shueb, et al.
Journal of Medicinal Chemistry|June 6, 2013
Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of toleranceMorgan Le Naour, Eyup Akgün, Ajay Yekkirala, et al.
Pageof 5